The company intends to funnel the proceeds from this market entry into its lead program, STX-1150, while simultaneously scaling its proprietary CRISPR platforms. These capital injections are slated to support ongoing research and development alongside general corporate requirements, supplementing the firm’s existing cash reserves.
In section Market Quotes
Scribe Therapeutics Targets Nasdaq Listing Amid Rising Losses
Scribe Therapeutics has officially filed for an initial public offering, seeking to trade under the ticker symbol SCTX on the Nasdaq. The biotechnology firm remains tight-lipped regarding the specific size and pricing of the offering, though it has granted underwriters a 30-day window to purchase additional shares.
Financial disclosures reveal a widening deficit for the quarter ending March 31, 2026. Scribe reported a net loss of $17.3 million, a sharp increase from the $3.4 million loss recorded during the same period the previous year. Revenue also faced significant downward pressure, dropping to $2.2 million from the $17.1 million posted twelve months earlier.
Comments (0)
No comments yet. Be the first!